FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/9TO & 1449B/PTO

Sheek

E

Application Number 10/750,940

Filing Date January 5, 2004

First Named Inventor Thorsteinn LOFTSSON et al.

(use as many sheets as necessary)

Examiner Name
Attorney Docket Number 016914-039

MAY 2 1 2004 **U.S. PATENT DOCUMENTS** Document Kind Code Name of Patentee or Applicant Issue/Publication Date Number (if known) of Cited Document (MM-DD-YYYY) 5,134,127 Stella et al. 07-28-1992 5,324,718 Loftsson 06-28-1994 5,376,645 Stella et al. 12-27-1994 5,472,954 Loftsson 12-05-1995

	FOREIGN PATENT DOCUMENTS						
Examiner	Document	Kind Code	Country	Date of Publication	Translation		
Initials	Number	(if known)	000111.19	(MM-DD-YYYY)	Yes	No	
MC AL	94/02518		wo	02-03-1994			
		}					

		NON-PATENT LITERATURE DOCUMENTS								
Examin Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journa serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.								
The AR		Oh et al, International Journal of Pharmaceutics, 73, pp. 23-31 (1991).								
	AS	Loftsson and Brewster, Pharm. Technol. Eur., 9(5), 26-34 (May 1997).								
	ΑT	Loftsson and Brewster, J. Pharm. Sci., 85(10), 1017-1025 (October 1996).								
	AU	Rajewski and Stella, <i>J. Pharm. Sci.</i> , 85 (11), 1142-1169 (November 1996).								
	ΑV	Irie and Uekama, <i>J. Pharm. Sci.</i> , 86(2), 147-162 (February 1997).								
7	ΑW	Stella and Rajewski, <i>Pharm. Res.</i> , 14(5), 556-567 (1997).								
1	ΑX	Loftsson, <i>Pharmazie</i> , 53, 733-740 (1998).								
	ΑY	Frömming and Szejtli, Cyclodextrins in Pharmacy, Kluwer Academic Publishers, Dordrecht, The Netherlands, pp. 105-107 (1994).								
-	ΑZ	Loftsson and Ólafsson, Int. J. Dermatol., 37, 241-246 (1998).								
<u> </u>	BR	Loftsson and Stefánsson, Drug. Dev. Ind. Pharm., 23 (5), 473-481 (1997).								
}	BS	Loftsson, Másson and Stefánsson, "Cyclodextrins as Permeation Enhancers", <i>Proceedings of the 17th Pharmaceutical Technology Conference and Exhibition</i> , volume 2, Dublin, pp. 313-324 (24-26 March 1998).								
The	ВТ	Schwartz, Rhodes and Cooper, J. Pharm. Sci., 66, 994-997 (July 1977).								
		-Loftseon and Beder, Acta Pharm. Nord., -1, -185-194 (1989) (kous No4).								
Re	BU	Loftsson and Sigudardóttir, "Cyclodextrins as skin penetration enhancers,", in J. Szejtli and Szente (eds)., Proceedings of the Eightl International Symposium on Cyclodextrins, Kluwer Academic Publishers, pp. 403-406 (1996).								
Examine Signatur		L. E. Crane Date Considered 01/13/2006								

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

COPY FOR [] File [] Applicant

10/750,940 _ PTO-1449 #1

Substitute for form 1	449A/PTO & 1	449B/PT	0	Con	if Known
لاسية.	ı	FIRS	_	Application Number	10/750,940
INFO	RMATI	ON E	DISCLOSURE	Filing Date	January 5, 2004
STAT	EMEN.	ГВҮ	APPLICANT	First Named Inventor	Thorsteinn LOFTSSON et al.
-	(use as man	y sheets	as necessary)	Examiner Name	
Sheet	2	of	2	Attorney Docket Number	016914-039

	•		NON-PATENT LITERATURE DOCUMENTS
	Examin Initial	1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	ALC BV		Roth, Eger and Troschütz, Pharmaceutical Chemistry, Volume 2: Drug Analysis, Ellis Horwood, pp. 308-309 (1991).
7	7	₿W	Gerecke, Br. J. Clin. Pharmac., 11S-16S (1983).
	(ВX	Pharmaceutical Chemistry, Volume 2: Drug Analysis, ed. H.J. Roth et al., pp. 302-311; 496-513; 518-525; 546-547; 580-581; 590-591; 594-597; 659-673; published by Ellis Horwood, London (1988).
		ВУ	Chemical Stability of Pharmaceuticals, A Handbook for Pharmacists, Second Edition, ed. Kenneth A. Connors et al, pp. 257-263; 675-684; 764-773; published by Wiley-Interscience; John Wiley & Sons, New York (1986).
		ΒZ	Stenlake, Foundations of Molecular Pharmacology, Volume 1, Medicinal and Pharmaceutical Chemistry, pp. 512-513, published by The Athlone Press, University of London (1979).
		CR	Junquera et al, J. Org. Chem., 63, pp. 4349-4358 (1998). (WWW publ.: 06/11/98).
Ì	5	CS	Li et al, Journal of Pharmaceutical Sciences, 87, No. 12, pp. 1535-1537 (December 1998).
Ì	5	CT	Krishnamoorthy et al., "Complexation of Weak Acids and Bases with Cyclodextrins: Effects of Substrate Ionization and the Estimation and Interpretation of Association Constants," <i>International J. of Pharmaceutical Advances</i> , 1 (3), 330-343 (Jan., 1996).
		CU	Loftsson et al., "Effects of 2-Hydroxypropyl-β-cyclodextrin on the Aqueous Solubility of Drugs and Transdermal Delivery of 17-β-Estradiol," Acta Pharm. Nord. 1 (4), 185-194 (1989).
	Re	CV	Menard et al., "Studies on the Effect of pH, Temperature and ring Size on the Complexation of Phenytoin with Cyclodextrins," <i>Pharm. Acta Helv.</i> , 63 (11), 303-308 (1988).
4			Leftssen et al., "The Influence of Water Soluble Polymere and pH on Hydroxylpropyl-β-cyclodextrin Complexation of Drugs," Drug Development and Industrial Pharmacy, 22 (5), 404-405 (1996); see also HCAPlus abstract.
	U	CW	Selva et al., "Study of the Salts of Organic Hydroxy Acids of the Terfenadine β-Cyclodextrin Complex in Solution of Mass Spectrometry," Journal of Mass Spectrometry, 30 (1), 219-220 (1995).
9	3	CX	Fenyvesi et al., "Enhancement of the Drug Solubilizing Capacity of Hydroxypropyl-β-cyclodextrin by Ternary Complex Formation," in The 7 th Cyclodextrin Symposium, T. Osa (ed.), Business Center for Academic Societies Japan, Tokyo, Japan, 1994, pages 414–418.
	Re	CY	Vikmon et al., "Terfenadine/Cyclodextrin/Hydroxyacid Multicomponent Complexes," in <u>The 7th Cyclodextrin Symposium</u> , T. Osa (ed.), Business Center for Academic Societies Japan, Tokyo, Japan, 1994, pages 480-483.
Ī		\overline{A}	·

_ •		11 11 11			
Examiner	L. E. Crane	18 V 10	Date	01/13/2006	
Signature	D. E. Grane	1/1/2 Cane	Considered	01/13/2000	
PEYABINED	. Initial if and account and id-	12.4.4.4.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO-892 U.S. Department of Commerce	Serial Number	•	Attachment to Paper Number	
	10/750,940	1623	01132006	
Notice of References Cited	APPLICANT(S)			
		Loftsson e	et al.	

U. S. Patent Documents

*		DOCUMENT NO.	DATE	NAME.	CLASS SUBCLAS		Filing Date If Appropriate
*	A	5,134,127 A	07/28/92	Stella et al.	514	058.000	
	В	6,699,849 B1	03/02/04	Loftsson et al.	514	058.000	

Foreign Patent Documents

*	DOCUMENT NO.					DATE	COUNTRY	ı	NAME	CLASS	SUB- CLASS		

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	R	Krishnamoorthy et al., "Complexation of Weak Acids and Bases with Cyclodextrins: Effects of Substrate Ionization and the Estimation and							
		Interpretation of Association Constants,"							
$ldsymbol{ldsymbol{ldsymbol{eta}}}$	•	International J. of Pharmaceutical Advances, 1(3), 330-343 (Jan., 1996).							
*	\mathbf{S}^{\dagger}	Loftsson et al. (I), "Effects of 2-Hydroxypropyl-\beta-cyclodextrin on the							
		Aqueous Solubility of Drugs and Transdermal Delivery of 17-B-Estradiol,"							
		Acta Pharm. Nord., 1(4), 185-194 (1989).							
*	T†	Menard et al., "Studies on the Effect of pH, Temperature and ring Size on the Complexation of Phenytoin with Cyclodextrine"							
*	T†	the Complexation of Phenytoin with Cyclodextrins,"							
*	T†								
*		the Complexation of Phenytoin with Cyclodextrins,"							
		the Complexation of Phenytoin with Cyclodextrins," Pharm. Acta Helv., 63(11), 303-308 (1988).							
		the Complexation of Phenytoin with Cyclodextrins," Pharm. Acta Helv., 63(11), 303-308 (1988). Loftsson et al. (II), "The Influence of Water-Soluble Polymers and pH on							

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

EXAMINER		DATE	page 1 of 2
L. E. Crane	MI Com	01/13/06	¥: Reference not presently available.
	*A copy of this	reference is not bei	ng furnished with this office action. g Procedure, Section 707.05(a).)

10/750,940 PTO-892 Copy for [] FILE APPLICANT [] IFW Attachment to P.N. 01132006

Form PTO-892 U.S. Department of Commerce	Serial Number	•	Attachment to Paper Number
	10/750,940	1623	01132006
Notice of References Cited	APPLICANT(S)		
·		Loftsson e	et al.

Other References (Including Author, Title, Date, Pertinent Pages, etc.)

*	\mathbf{V}^{\dagger}	Selva et al., "Study of the Salts of Organic Hydroxy Acids of the						
•		Terfenadine \(\beta\)-Cyclodextrin Complex in Solution by Mass Spectrometry,"						
		Journal of Mass Spectrometry, 30(1), 219-220 (1995).						
*	W†	Fenyvesi et al., "Enhancement of the Drug Solubilizing Capacity of						
-		Hydroxypropyl-ß-cyclodextrin by Ternary Complex Formation," in						
l		The 7th Cyclodextrin Symposium, T. Osa (ed.), Business Center for						
		Academic Societies Japan, Tokyo, Japan, 1994, pages 414-418.						
*	\mathbf{X}^{\dagger}	Vikmon et al., "Terfenadine/Cyclodextrin/Hydroxyacid Multicomponent						
		Complexes," in The 7th Cyclodextrin Symposium, T. Osa (ed.), Business						
		Center for Academic Societies Japan, Tokyo, Japan, 1994, pages 480-483.						

[†] Month of publication data is unavailable. Issue Number information is provided whenever possible following the volume number in parentheses.

10/750,940 PTO-892 Copy for [] FILE APPLICANT [] IF